Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 7/20 | 0.52 |
| ▸ | FAAH | O00519 | 12/20 | 0.46 |
| ▸ | CES1 | P23141 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15591647 | 0.85 | CES2 (0.40) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL8115343 | 0.84 | FAAH (0.56) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL9767600 | 0.80 | FAAH (0.67) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL18965382 | 0.79 | CES2 (0.46) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL15744200 | 0.79 | CES2 (0.46) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL12396593 | 0.78 | CES2 (0.54) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL1706449 | 0.78 | CES2 (0.54) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL20654764 | 0.77 | CES2 (0.59) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL18022083 | 0.77 | CES2 (0.44) | CES2FAAHCES1MEN1CYP1A2 | |
| SCHEMBL3001830 | 0.77 | CES2 (0.44) | CES2FAAHCES1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382272-B2 | Methods of making lubiprostone and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2016-07-05 | — | — | US | disclosed |
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-03-15 | — | — | US | disclosed |
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065409-A1 | METHODS OF MAKING LUBIPROSTONE AND INTERMEDIATES THEREOF | PTGIS, LSS, SQLE | CES2 1201/4885FAAH 2451/4885CES1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.